1-氟-2,6-二氯吡啶三氟甲磺酸盐 | 130433-68-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-氟-2,6-二氯吡啶三氟甲磺酸盐
• 中文别名: 2,6-二氯-1-氟吡啶三氟甲磺酸盐[氟化试剂]；2,6-二氯-1-氟吡啶三氟甲磺酸盐
• 英文名称: 2,6-dichloro-1-fluoropyridinium triflate
• 英文别名: N-fluoro-2,6-dichloropyridinium triflate；2,6-di-chloro-N-fluoropyridinium triflate；1-fluoro-2,6-dichloropyridinium triflate；2,6-dichloro-1-fluoropyridin-1-ium;trifluoromethanesulfonate
• CAS: 130433-68-0
• 化学式: CF₃O₃S*C₅H₃Cl₂FN
• 分子量: 316.06
• InChiKey: KDFRVNARKRKXQQ-UHFFFAOYSA-M

物化性质

• 熔点：
  176-182 °C
• 稳定性/保质期：
  在常温常压下，该物质是稳定的。

计算性质

• 辛醇/水分配系数(LogP)：
  2.06
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  69.5
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• TSCA：
  No
• 危险等级：
  IRRITANT
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• WGK Germany：
  3
• 海关编码：
  2933399090
• 危险品运输编号：
  UN 3261 8 / PGII
• 危险类别：
  IRRITANT
• 包装等级：
  II
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H314

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 2,6-Dichloro-1-fluoropyridinium triflate
CAS-No. : 130433-68-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin corrosion (Category 1B)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Causes severe burns.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Danger
Hazard statement(s)
H314 Causes severe skin burns and eye damage.
Precautionary statement(s)
P280 Wear protective gloves/ protective clothing/ eye protection/ face
protection.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P310 Immediately call a POISON CENTER or doctor/ physician.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R35 Causes severe burns.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37/39 Wear suitable protective clothing, gloves and eye/face protection.
S45 In case of accident or if you feel unwell, seek medical advice immediately
(show the label where possible).
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 1-Fluoro-2,6-dichloropyridinium triflate
Formula : C6H3Cl2F4NO3S
Molecular Weight : 316,06 g/mol
Component Concentration
2,6-Dichloro-1-fluoropyridinium triflate
CAS-No. 130433-68-0 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Take off contaminated clothing and shoes immediately. Wash off with soap and plenty of water. Consult a
physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water.
Consult a physician.
Most important symptoms and effects, both acute and delayed
burning sensation, Cough, wheezing, laryngitis, Shortness of breath, spasm, inflammation and edema of the
larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, Material is extremely
destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
no data available
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Handle and store under inert gas. Moisture sensitive. Light sensitive.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such as
NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 121 - 126 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
Solubility in other Methanol
solvents

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents, Bases
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Material is extremely destructive to the tissue of
the mucous membranes and upper respiratory tract.
Ingestion May be harmful if swallowed. Causes burns.
Skin May be harmful if absorbed through skin. Causes skin burns.
Eyes Causes eye burns.
Signs and Symptoms of Exposure
burning sensation, Cough, wheezing, laryngitis, Shortness of breath, spasm, inflammation and edema of the
larynx, spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, Material is extremely
destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: 3261 IMDG: 3261 IATA: 3261
UN proper shipping name
ADR/RID: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S. (2,6-Dichloro-1-fluoropyridinium triflate)
IMDG: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S. (2,6-Dichloro-1-fluoropyridinium triflate)
IATA: Corrosive solid, acidic, organic, n.o.s. (2,6-Dichloro-1-fluoropyridinium triflate)
Transport hazard class(es)
ADR/RID: 8 IMDG: 8 IATA: 8
Packaging group
ADR/RID: II IMDG: II IATA: II
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2011 Co. License granted to make unlimited paper copies for internal use only.
The above information is believed to be correct but does not purport to be all inclusive and shall be used
only as a guide. The information in this document is based on the present state of our knowledge and is
applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Co., shall not be held liable for any damage
resulting from handling or from contact with the above product. See reverse side of invoice or packing slip
for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  1-氟-2,6-二氯吡啶三氟甲磺酸盐 在 水 作用下， 反应 6.0h， 以35%的产率得到N-Fluoro-6-chloro-2-pyridone
  参考文献：
  名称：

  N-氟吡啶鎓盐的合成及性质

  摘要：

  各种稳定的 N-氟吡啶鎓盐，带有非亲核性或弱亲核性抗衡阴离子，例如 TfO−、FSO3−、BF4−、SbF6−、ClO4−、CH3SO3− 等，或带有给电子或吸电子取代基合成了吡啶环上的化合物并研究了它们的性质。还合成了 N-氟吡啶鎓-2-磺酸盐、N-氟喹啉鎓三氟甲磺酸盐和高度受阻的 N-氟-2,6-二-叔丁基吡啶鎓盐。它们是通过不稳定的吡啶-F2 化合物的抗衡阴离子置换反应、吡啶盐与质子酸或甲硅烷基酯与 F2 的氟化和/或吡啶的路易斯酸络合物的氟化来合成的。详细检查了每种方法的范围。每种 N-氟吡啶鎓盐都被指定为第一个稳定的 1：1 基于光谱和元素分析的吡啶核和卤素原子的盐结构。稳定性取决于抗衡阴离子的亲核性或碱性以及环的电子性质或位置...

  DOI：

  10.1246/bcsj.64.1081
• 作为产物：
  描述：

  2,6-二氯吡啶 、 三氟甲磺酸 在 fluorine 作用下， 以 various solvent(s) 为溶剂， 反应 3.0h， 以62%的产率得到1-氟-2,6-二氯吡啶三氟甲磺酸盐
  参考文献：
  名称：

  N-氟吡啶鎓盐的合成及性质

  摘要：

  各种稳定的 N-氟吡啶鎓盐，带有非亲核性或弱亲核性抗衡阴离子，例如 TfO−、FSO3−、BF4−、SbF6−、ClO4−、CH3SO3− 等，或带有给电子或吸电子取代基合成了吡啶环上的化合物并研究了它们的性质。还合成了 N-氟吡啶鎓-2-磺酸盐、N-氟喹啉鎓三氟甲磺酸盐和高度受阻的 N-氟-2,6-二-叔丁基吡啶鎓盐。它们是通过不稳定的吡啶-F2 化合物的抗衡阴离子置换反应、吡啶盐与质子酸或甲硅烷基酯与 F2 的氟化和/或吡啶的路易斯酸络合物的氟化来合成的。详细检查了每种方法的范围。每种 N-氟吡啶鎓盐都被指定为第一个稳定的 1：1 基于光谱和元素分析的吡啶核和卤素原子的盐结构。稳定性取决于抗衡阴离子的亲核性或碱性以及环的电子性质或位置...

  DOI：

  10.1246/bcsj.64.1081
• 作为试剂：
  描述：

  1-苄基哌啶 在 甲醇 、 N-碘代丁二酰亚胺 、 1-氟-2,6-二氯吡啶三氟甲磺酸盐 、 magnesium 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成
  参考文献：
  名称：

  环胺的氧化性β-C–H磺酰化†

  摘要：

  描述了用于叔环胺的脱氢β-磺酰基化的无过渡金属的策略。N-碘琥珀酰亚胺可促进在叔胺氮原子上位于β的C–H键处的区域选择性氧化磺酰化，从而在循环系统中安装了烯胺基砜官能团。证明了温和的反应条件，广泛的官能团耐受性和广泛的底物范围。利用了烯胺基砜的亲核特性，证明了其在支架多样化中的潜在应用。

  DOI：

  10.1039/c7sc04900e

文献信息

• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050020645A1

  公开（公告）日：2005-01-27

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  通用式（1）表示的化合物： Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4（1） 其中R1和R2是氢原子或类似物；Q1是饱和或不饱和的、5-或6-成员环烃基，可以被取代，或类似物；Q2是单键或类似物；Q3是一个基团，其中Q5是具有1至8个碳原子的烷基基团，或类似物；T0和T1是羰基团或类似物；其盐、溶剂合物或N-氧化物。 该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成，或抽血时的血液凝结。
• Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta
  申请人：Acadia Pharmaceuticals Inc.

  公开号：EP2554532A1

  公开（公告）日：2013-02-06

  Disclosed herein are novel di-aromatic compounds of the general formula (I): Also pharmaceutical compositions comprising the novel compounds and the use of the novel compounds in treatment and prevention of diseases and disorders related to estrogen receptors are disclosed. Furthermore, methods for treating and preventing diseases and disorders related to estrogen receptors by administration of the novel compounds are disclosed.

  本发明公开了通式(I)的新型二芳香化合物： 还公开了包含该新型化合物的药物组合物，以及新型化合物在治疗和预防与雌激素受体相关的疾病和障碍中的应用。此外，还公开了通过施用新型化合物来治疗和预防与雌激素受体相关的疾病和障碍的方法。
• [EN] DIPHENYL SUBSTITUTED CYCLOHEXANE DERIVATIVES, USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS BETA<br/>[FR] DÉRIVÉS DE CYCLOHEXANE À SUBSTITUTION DIPHÉNYLE, UTILES EN TANT QUE MODULATEURS DES RÉCEPTEURS BÊTA DES OESTROGÈNES
  申请人：ACADIA PHARM INC

  公开号：WO2013017619A1

  公开（公告）日：2013-02-07

  Disclosed herein are novel di-aromatic compounds of the general formula (I). Also pharmaceutical compositions comprising the novel compounds and the use of the novel compounds in treatment and prevention of diseases and disorders related to estrogen receptors are disclosed. Furthermore, methods for treating and preventing diseases and disorders related to estrogen receptors by administration of the novel compounds are disclosed.

  本发明公开了通式(I)的新型二芳香化合物。还公开了包含该新型化合物的药物组合物，以及该新型化合物在治疗和预防与雌激素受体相关的疾病和障碍中的应用。此外，还公开了通过给予该新型化合物来治疗和预防与雌激素受体相关的疾病和障碍的方法。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS POUR TRAITER LES MALADIES NEURODÉGÉNÉRATIVES
  申请人：ACADIA PHARM INC

  公开号：WO2014125121A1

  公开（公告）日：2014-08-21

  The present application relates to a composition comprising a selective androgen modulating compound of formula (I) and selective estrogen receptor β agonist of formula (II). The present application also relates to the use of a selective androgen modulating compound of formula (I) in combination with a selective estrogen receptor β agonist of formula (II) in the treatment or prevention of neurodegenerative diseases or disorders,such as Alzheimer's disease, Huntigton's disease, Parkinson's disease, depression, anxiety, multiple sclerosis, symptoms associated with or caused by multiple sclerosis, and acute or chronic pain.

  本申请涉及一种包含公式（I）的选择性雄激素调节化合物和公式（II）的选择性雌激素受体β激动剂的组合物。本申请还涉及将公式（I）的选择性雄激素调节化合物与公式（II）的选择性雌激素受体β激动剂结合使用，用于治疗或预防神经退行性疾病或障碍，例如阿尔茨海默病、亨廷顿病、帕金森病、抑郁症、焦虑症、多发性硬化症、与多发性硬化症相关或由其引起的症状，以及急性或慢性疼痛。
• 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME
  申请人：Shibata Norio

  公开号：US20110319637A1

  公开（公告）日：2011-12-29

  A 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative as a monofluoromethyl group introduction agent that is effective as an intermediate in pharmaceutical and agrochemical synthesis, a production method thereof, and a production method of a monofluoromethyl group-containing compound using this 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative are provided. The 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative represented by the following general formula (1) (wherein R 1 , R 2 , R 3 , and R 4 each independently represent a hydrogen atom, a straight-chain or branched alkyl group having 1 to 4 carbon atoms, a straight-chain or branched alkyloxy group having 1 to 4 carbon atoms, a halogen atom, a nitro group, or a cyano group), the production method thereof, and various monofluoromethyl group-containing compounds are manufactured using this 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative as a monofluoromethylating agent.

  一种2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物作为单氟甲基基团引入剂，可作为制药和农药合成中间体，提供其生产方法，以及使用该2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物制备含单氟甲基基团的化合物的生产方法。所述2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物由下述通用式（1）表示（其中R1、R2、R3和R4各自独立地表示氢原子、具有1至4个碳原子的直链或支链烷基基团、具有1至4个碳原子的直链或支链烷氧基基团、卤素原子、硝基团或氰基团），提供其生产方法，并使用该2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物作为单氟甲基化剂制造各种含单氟甲基基团的化合物。

表征谱图